Developer docs
API playgroundTry for free, no card

Search company profiles

Théa Pharma

Full company profile

uuid000lmlq

Namestring
Théa Pharma
Legal namestring
Théa Pharma S.A.S.
Websiteurl
theapharma.fr
Company typeenum
Private
Founded yearint
1993
Descriptiontext

Théa Pharma is a French, family-owned specialty pharmaceutical company exclusively dedicated to ophthalmology, headquartered at 37 rue Georges Besse in Clermont-Ferrand, France, and operating under the legal entity Théa Pharma S.A.S. The company sells prescription and over-the-counter ophthalmic products — eye drops, gels, ointments, eyelid hygiene solutions, antibiotics, and ocular nutrition supplements — addressing ten therapeutic areas including glaucoma, dry eye, ocular allergy, infection, inflammation, anesthesia, mydriasis, ocular herpes, nutrition, and eyelid hygiene. Its core proprietary technology is the ABAK multi-dose bottle system, invented by Théa in the 1990s after ten years of research, which was the first delivery system capable of providing preservative-free ophthalmic drops in a multi-dose container; this platform anchors a portfolio that emphasizes preservative-free formulations and includes branded lines such as the BLEPHA family (BLEPHASOL, BLEPHAGEL, BLEPHADERM, BLEPHADEMODEX, BLEPHACLEAN, BLEPHA EYEBAG), antibiotic treatments (APROKAM, AZYTER), and the Nutrof nutritional supplement range.

The company is privately held and controlled by the Chibret family, with founder Henri Chibret and his descendant Jean-Frédéric Chibret currently serving as President. Théa operates through an enterprise field sales motion targeting ophthalmologists and eye care professionals, with products distributed via pharmacies, hospitals, and eye care clinics rather than direct-to-consumer channels; revenue is generated through one-time sale of pharmaceutical products across 24+ countries spanning Europe, North America, and South America. Pricing is not publicly disclosed and certain formulations require prescription. The company emphasizes 100% European manufacturing and runs the Théa Academy professional education platform alongside participation in major congresses (ESCRS, AAO, EVER) for medical engagement. Recent strategic activity includes the August 2025 inauguration of a Stockholm office for the Nordic region, April 2026 membership in the Initiative Pharma French industry alliance, and a February 2026 greenhouse gas reduction roadmap aligned with international climate objectives.

No revenue, headcount, or funding data is publicly disclosed, and the company shows no evidence of AI/ML capability development, M&A activity, or external institutional investment.

Short descriptiontext

Théa Pharma is a French, family-owned specialty pharmaceutical company exclusively dedicated to ophthalmology, selling preservative-free eye drops, eyelid hygiene solutions, and ocular nutrition products to ophthalmologists and eye care professionals across more than 20 countries via pharmacy distribution.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersClermont-ferrand, France
HQ citystring
Clermont-ferrand
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
ophthalmic pharmaceuticals, preservative-free eye drops, eyelid hygiene products, ocular therapeutics, ophthalmic drug delivery
Industry3 codes
PRIMARYHLAIACAK
Ophthalmology Specialty Pharmaceuticals
SECONDARYHLAHAIAL
Ocular Drug Delivery Devices (Eye Droppers/Inserts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
SECONDARYHLAIADAF
Eye, Ear & Nasal Care
Healthcare & Life Sciences/Pharmaceuticals/Over-the-Counter (OTC) Medicines
NAICS code1 code
  • Ophthalmic Goods Manufacturing339115
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Ophthalmic Goods3851
Product category
Ophthalmic Pharmaceuticals
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Ophthalmic pharmaceuticals
TypeOne Time License
Description

Théa generates revenue through the sale of prescription and OTC ophthalmic pharmaceutical products including eye drops, gels, ointments, and eyelid hygiene products for various eye conditions.

fr.thea.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Supply Chain, Operations, Personnel, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1ABAK
Description

Multi-dose bottle technology capable of delivering preservative-free eye drops, developed after ten years of research in the 1990s.

fr.thea.com
+1 more record
Core offering1 text field

Théa Pharma is a pharmaceutical company exclusively dedicated to ophthalmology, manufacturing and selling a comprehensive portfolio of preservative-free ophthalmic products including eye drops, gels, ointments, eyelid hygiene solutions, and ocular nutrition supplements. Its core proprietary technology is the ABAK multi-dose bottle system, which enables delivery of preservative-free eye drops in multi-dose containers. Products cover 10 ocular health domains: infection, inflammation, anesthesia, allergy, glaucoma, dry eye, mydriasis, ocular nutrition, herpes, and eyelid hygiene.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Théa Pharma is a pharmaceutical company exclusively dedicated to ophthalmology, offering a comprehensive portfolio of eye care products. The company provides treatments across multiple therapeutic areas including infection, inflammation, anesthesia, allergy, glaucoma, dry eye, mydriasis, and ocular nutrition. Théa's products are primarily preservative-free formulations delivered through innovative delivery systems. Key product lines include the ABAK® multi-dose preservative-free bottle technology, the BLEPHA® family for eyelid hygiene and care (BLEPHASOL®, BLEPHAGEL®, BLEPHADERM®, BLEPHADEMODEX®, BLEPHACLEAN®), antibiotic treatments like APROKAM® and AZYTER®, and nutritional supplements under the Nutrof® brand. The company emphasizes its preservative-free formulations, with products available in both multi-dose ABAK® bottles and unit-dose vials.

Product and service9 records
1BLEPHASOL®
CategoryCosmetic product (eyelid hygiene)
Description

Micellar lotion for daily hygiene of sensitive eyelids and lid margin. Removes impurities, debris, crusts, and makeup from the eyelid and lash line.

2BLEPHAGEL®
CategoryMedical device/cosmetic (eyelid hygiene)
Description

Gel for daily hygiene of eyelids and lashes. Formula adapted for cleaning the lid margin when flaky and soiled with impurities.

3BLEPHADERM®
CategoryCosmetic product (eyelid care)
Description

Soothing cream for eyelids and eye contour area.

4BLEPHADEMODEX®
CategoryClass IIa medical device (eyelid hygiene)
Description

Class IIa medical device recommended for eyelid hygiene in case of Demodex infection. Sterile, ready-to-use wipes for eyelid hygiene when affected by Demodex.

5BLEPHACLEAN®
CategoryClass IIa medical device (eyelid hygiene)
Description

High-tolerance, preservative-free cleansing lotion. Sterile, pre-impregnated wipes recommended for daily eyelid hygiene and sensitive skin.

6BLEPHA EYEBAG®
CategoryEyelid care product
Description

Product for eyelid care and treatment.

7APROKAM®
CategoryAntibiotic ophthalmic product
Description

Antibiotic eye product for treating ocular infections.

8AZYTER® 6 UNIDOSES
CategoryAntibiotic eye drops (ophthalmic antibiotic)
Description

Antibiotic eye drops in unit-dose vials for treating ocular infections.

9Nutrof®
CategoryNutritional supplement brand for ocular health
Description

One of the pioneers in the ocular nutrition segment, Nutrof has become a reference in the field of nutritional supplements for eye health.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Partnership1 partner
1Initiative Pharma
Strategic tierMinorTypeOthersAnnounced on2026-01-01
Description

Théa joined Initiative Pharma, a new French pharmaceutical industry alliance. This union brings together committed industrial players focused on investment and innovation in France, with a clear ambition to strengthen sovereignty in the pharmaceutical sector.

fr.thea.com
Recent move1 record

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1Santen Pharmaceutical
TypeDirect peer
Description

Japanese specialty pharmaceutical company focused on ophthalmology with a global commercial footprint. Directly comparable to Théa as a prescription ophthalmic pharma specialist covering glaucoma, dry eye, and ocular surface diseases.

TypeBroad incumbent
Description

Global leader in eye care with pharmaceutical and surgical/device businesses spanning cataract, glaucoma, dry eye and contact lenses. Larger and more diversified incumbent serving the same ophthalmologist customers.

TypeBroad incumbent
Description

Diversified ophthalmic company offering prescription ophthalmic pharmaceuticals, OTC eye care, and vision care products. Competes head-on with Théa in prescription eye drops and OTC eyelid hygiene.

TypeBroad incumbent
Description

Owner of the former Allergan Aesthetics/eye care franchise with leading ophthalmic pharmaceutical brands (e.g., RESTASIS, LUMIGAN). Targets the same ophthalmologist channel as Théa with significantly greater resources.

TypeEmerging player
Description

France-based ophthalmic specialty company developing therapeutics for glaucoma and ocular surface diseases. Closely comparable as a smaller, French-rooted ophthalmic pharma peer with overlapping therapeutic areas.

TypeEmerging player
Description

US-based biopharmaceutical company focused on ophthalmic therapeutics using innovative drug delivery platforms. Comparable as a smaller specialty player competing on differentiated ophthalmic delivery technology.

TypeEmerging player
Description

US specialty ophthalmic pharma commercializing sustained-release drug delivery treatments for retinal and ocular surface diseases. Overlaps with Théa in ophthalmic drug delivery innovation and prescriber channel.

TypeEmerging player
Description

US-based ophthalmic specialty pharma developing therapies for eye diseases. Comparable as a smaller ophthalmic-focused player competing for ophthalmologist mindshare in niche indications.

9Horizon Therapeutics
TypeBroad incumbent
Description

Specialty biopharma with significant ophthalmic franchise (TEPEZZA for thyroid eye disease). Competes for ophthalmologist prescribing and biologic ophthalmology indications adjacent to Théa's portfolio.

TypeRegional player
Description

German-headquartered ophthalmic pharmaceutical company with a strong preservative-free and dry-eye portfolio. Directly comparable to Théa in European preservative-free ophthalmology and overlapping therapeutic categories.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Théa Pharma

Ophthalmic Pharmaceuticalstheapharma.fr

Théa Pharma is a French, family-owned specialty pharmaceutical company exclusively dedicated to ophthalmology, selling preservative-free eye drops, eyelid hygiene solutions, and ocular nutrition products to ophthalmologists and eye care professionals across more than 20 countries via pharmacy distribution.

What Théa Pharma does

Théa Pharma is a French, family-owned specialty pharmaceutical company exclusively dedicated to ophthalmology, headquartered at 37 rue Georges Besse in Clermont-Ferrand, France, and operating under the legal entity Théa Pharma S.A.S. The company sells prescription and over-the-counter ophthalmic products — eye drops, gels, ointments, eyelid hygiene solutions, antibiotics, and ocular nutrition supplements — addressing ten therapeutic areas including glaucoma, dry eye, ocular allergy, infection, inflammation, anesthesia, mydriasis, ocular herpes, nutrition, and eyelid hygiene. Its core proprietary technology is the ABAK multi-dose bottle system, invented by Théa in the 1990s after ten years of research, which was the first delivery system capable of providing preservative-free ophthalmic drops in a multi-dose container; this platform anchors a portfolio that emphasizes preservative-free formulations and includes branded lines such as the BLEPHA family (BLEPHASOL, BLEPHAGEL, BLEPHADERM, BLEPHADEMODEX, BLEPHACLEAN, BLEPHA EYEBAG), antibiotic treatments (APROKAM, AZYTER), and the Nutrof nutritional supplement range.

The company is privately held and controlled by the Chibret family, with founder Henri Chibret and his descendant Jean-Frédéric Chibret currently serving as President. Théa operates through an enterprise field sales motion targeting ophthalmologists and eye care professionals, with products distributed via pharmacies, hospitals, and eye care clinics rather than direct-to-consumer channels; revenue is generated through one-time sale of pharmaceutical products across 24+ countries spanning Europe, North America, and South America. Pricing is not publicly disclosed and certain formulations require prescription. The company emphasizes 100% European manufacturing and runs the Théa Academy professional education platform alongside participation in major congresses (ESCRS, AAO, EVER) for medical engagement. Recent strategic activity includes the August 2025 inauguration of a Stockholm office for the Nordic region, April 2026 membership in the Initiative Pharma French industry alliance, and a February 2026 greenhouse gas reduction roadmap aligned with international climate objectives.

No revenue, headcount, or funding data is publicly disclosed, and the company shows no evidence of AI/ML capability development, M&A activity, or external institutional investment.

Théa Pharma firmographics

Firmographics
Name
Théa Pharma
Legal name
Théa Pharma S.A.S.
Website
https://theapharma.fr
Company type
Private
Founded year
1993
Operating status
Operating
Headcount range
11–50 employees
Short description
Théa Pharma is a French, family-owned specialty pharmaceutical company exclusively dedicated to ophthalmology, selling preservative-free eye drops, eyelid hygiene solutions, and ocular nutrition products to ophthalmologists and eye care professionals across more than 20 countries via pharmacy distribution.
Ownership category
akta.pro rank

Théa Pharma industry classification

Industry
Product category
Ophthalmic Pharmaceuticals
NAICS
Ophthalmic Goods Manufacturing (339115)
SIC
Pharmaceutical Preparations (2834), Ophthalmic Goods (3851)
akta.pro industry
PRIMARYHLAIACAK
Ophthalmology Specialty Pharmaceuticals
SECONDARYHLAHAIAL
Ocular Drug Delivery Devices (Eye Droppers/Inserts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
SECONDARYHLAIADAF
Eye, Ear & Nasal Care
Healthcare & Life Sciences/Pharmaceuticals/Over-the-Counter (OTC) Medicines

Keywords

  • Ophthalmic pharmaceuticals
  • Preservative-free eye drops
  • Eyelid hygiene products
  • Ocular therapeutics
  • Ophthalmic drug delivery

Where Théa Pharma is headquartered

Location

Headquarters

HQ city
Clermont-ferrand
HQ country
France
HQ region
Europe

Offices1 record

Markets served

Théa Pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Operations, Personnel, Marketing or Sales

Revenue model

  1. Ophthalmic pharmaceuticals: Théa generates revenue through the sale of prescription and OTC ophthalmic pharmaceutical products including eye drops, gels, ointments, and eyelid hygiene products for various eye conditions.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Théa Pharma product offering

Product offering

Core offering

Théa Pharma is a pharmaceutical company exclusively dedicated to ophthalmology, manufacturing and selling a comprehensive portfolio of preservative-free ophthalmic products including eye drops, gels, ointments, eyelid hygiene solutions, and ocular nutrition supplements. Its core proprietary technology is the ABAK multi-dose bottle system, which enables delivery of preservative-free eye drops in multi-dose containers. Products cover 10 ocular health domains: infection, inflammation, anesthesia, allergy, glaucoma, dry eye, mydriasis, ocular nutrition, herpes, and eyelid hygiene.

Product overview

Théa Pharma is a pharmaceutical company exclusively dedicated to ophthalmology, offering a comprehensive portfolio of eye care products. The company provides treatments across multiple therapeutic areas including infection, inflammation, anesthesia, allergy, glaucoma, dry eye, mydriasis, and ocular nutrition. Théa's products are primarily preservative-free formulations delivered through innovative delivery systems. Key product lines include the ABAK® multi-dose preservative-free bottle technology, the BLEPHA® family for eyelid hygiene and care (BLEPHASOL®, BLEPHAGEL®, BLEPHADERM®, BLEPHADEMODEX®, BLEPHACLEAN®), antibiotic treatments like APROKAM® and AZYTER®, and nutritional supplements under the Nutrof® brand. The company emphasizes its preservative-free formulations, with products available in both multi-dose ABAK® bottles and unit-dose vials.

Differentiator

Problem solved

Functional benefit

Brands

  • ABAK: Multi-dose bottle technology capable of delivering preservative-free eye drops, developed after ten years of research in the 1990s.
  • Nutrof

Products and services

  • BLEPHASOL® Micellar lotion for daily hygiene of sensitive eyelids and lid margin. Removes impurities, debris, crusts, and makeup from the eyelid and lash line.
  • BLEPHAGEL® Gel for daily hygiene of eyelids and lashes. Formula adapted for cleaning the lid margin when flaky and soiled with impurities.
  • BLEPHADERM® Soothing cream for eyelids and eye contour area.
  • BLEPHADEMODEX® Class IIa medical device recommended for eyelid hygiene in case of Demodex infection. Sterile, ready-to-use wipes for eyelid hygiene when affected by Demodex.
  • BLEPHACLEAN® High-tolerance, preservative-free cleansing lotion. Sterile, pre-impregnated wipes recommended for daily eyelid hygiene and sensitive skin.
  • BLEPHA EYEBAG® Product for eyelid care and treatment.
  • APROKAM® Antibiotic eye product for treating ocular infections.
  • AZYTER® 6 UNIDOSES Antibiotic eye drops in unit-dose vials for treating ocular infections.
  • Nutrof® One of the pioneers in the ocular nutrition segment, Nutrof has become a reference in the field of nutritional supplements for eye health.

Companies that use Théa Pharma

Customer profile

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Théa Pharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Théa Pharma partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Initiative PharmaminorOthers · 1 January 2026Théa joined Initiative Pharma, a new French pharmaceutical industry alliance. This union brings together committed industrial players focused on investment and innovation in France, with a clear ambition to strengthen sovereignty in the pharmaceutical sector.

Scale indicators1 record

Recent moves1 record

Expansion highlights5 records

Théa Pharma competitors and assessment

Company assessment

Direct peers

  • Santen Pharmaceutical: Japanese specialty pharmaceutical company focused on ophthalmology with a global commercial footprint. Directly comparable to Théa as a prescription ophthalmic pharma specialist covering glaucoma, dry eye, and ocular surface diseases.

Broad incumbents

  • Alcon: Global leader in eye care with pharmaceutical and surgical/device businesses spanning cataract, glaucoma, dry eye and contact lenses. Larger and more diversified incumbent serving the same ophthalmologist customers.
  • Bausch + Lomb: Diversified ophthalmic company offering prescription ophthalmic pharmaceuticals, OTC eye care, and vision care products. Competes head-on with Théa in prescription eye drops and OTC eyelid hygiene.
  • Allergan (AbbVie): Owner of the former Allergan Aesthetics/eye care franchise with leading ophthalmic pharmaceutical brands (e.g., RESTASIS, LUMIGAN). Targets the same ophthalmologist channel as Théa with significantly greater resources.
  • Horizon Therapeutics: Specialty biopharma with significant ophthalmic franchise (TEPEZZA for thyroid eye disease). Competes for ophthalmologist prescribing and biologic ophthalmology indications adjacent to Théa's portfolio.

Emerging players

  • Nicox: France-based ophthalmic specialty company developing therapeutics for glaucoma and ocular surface diseases. Closely comparable as a smaller, French-rooted ophthalmic pharma peer with overlapping therapeutic areas.
  • Ocular Therapeutix: US-based biopharmaceutical company focused on ophthalmic therapeutics using innovative drug delivery platforms. Comparable as a smaller specialty player competing on differentiated ophthalmic delivery technology.
  • EyePoint Pharmaceuticals: US specialty ophthalmic pharma commercializing sustained-release drug delivery treatments for retinal and ocular surface diseases. Overlaps with Théa in ophthalmic drug delivery innovation and prescriber channel.
  • Kala Bio: US-based ophthalmic specialty pharma developing therapies for eye diseases. Comparable as a smaller ophthalmic-focused player competing for ophthalmologist mindshare in niche indications.

Regional players

  • URSAPHARM: German-headquartered ophthalmic pharmaceutical company with a strong preservative-free and dry-eye portfolio. Directly comparable to Théa in European preservative-free ophthalmology and overlapping therapeutic categories.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Théa Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Théa Pharma leadership team

Management profile

Number of profiles

Profiles5 records

Théa Pharma funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Théa Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Théa Pharma

What does Théa Pharma do?

Théa Pharma is a pharmaceutical company exclusively dedicated to ophthalmology, manufacturing and selling a comprehensive portfolio of preservative-free ophthalmic products including eye drops, gels, ointments, eyelid hygiene solutions, and ocular nutrition supplements. Its core proprietary technology is the ABAK multi-dose bottle system, which enables delivery of preservative-free eye drops in multi-dose containers. Products cover 10 ocular health domains: infection, inflammation, anesthesia, allergy, glaucoma, dry eye, mydriasis, ocular nutrition, herpes, and eyelid hygiene.

Is Théa Pharma a public or private company?

Théa Pharma is a private company. It is classified as family owned and is currently operating.

When was Théa Pharma founded?

Théa Pharma was founded in 1993. It employs 11 to 50 people.

Where is Théa Pharma based?

Théa Pharma is headquartered in Clermont-ferrand, France, in the Europe region.

How does Théa Pharma make money?

One revenue line is on record: ophthalmic pharmaceuticals.

Who are Théa Pharma's main competitors?

Santen Pharmaceutical is listed as a direct peer. Broad incumbents are Alcon, Bausch + Lomb, Allergan (AbbVie) and Horizon Therapeutics. Emerging players are Nicox, Ocular Therapeutix, EyePoint Pharmaceuticals and Kala Bio. URSAPHARM is listed as a regional player.

Does Théa Pharma have an API?

No public API is recorded for Théa Pharma.

What industry is Théa Pharma in?

Théa Pharma's product category is Ophthalmic Pharmaceuticals. Its primary akta.pro industry code is HLAIACAK, Ophthalmology Specialty Pharmaceuticals, with a secondary code of HLAHAIAL, Ocular Drug Delivery Devices (Eye Droppers/Inserts). Its NAICS code is 339115 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales